Evidence map›Paper›PMID 39603607›Full record

ArticleEndocrine journal2025

Clinical comparison and genetic analysis in pheochromocytoma with primary aldosteronism.

Xurong Mai, Mitsuhiro Kometani, Toshiaki Kato, Ko Aiga, Shigehiro Karashima, Daisuke Aono, Seigo Konishi, Koshiro Nishimoto, Kazuyoshi Hosomichi, Atsushi Watanabe and 3 more

Abstract readComparative Study
In one paragraph

Article in Endocrine journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xurong MaiDepartment of Health Promotion and Medicine of the Future, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan.ORCID http://orcid.org/0000-0003-0330-5662
Mitsuhiro KometaniDepartment of Health Promotion and Medicine of the Future, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan.ORCID http://orcid.org/0000-0003-0461-3018
Toshiaki KatoDepartment of Health Promotion and Medicine of the Future, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan.
Ko AigaDepartment of Health Promotion and Medicine of the Future, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan.
Shigehiro KarashimaDepartment of Health Promotion and Medicine of the Future, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan.ORCID http://orcid.org/0000-0002-4084-9653
Daisuke AonoDepartment of Health Promotion and Medicine of the Future, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan.
Seigo KonishiDepartment of Health Promotion and Medicine of the Future, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan.
Koshiro NishimotoDepartment of Uro-Oncology, International Medical Center Saitama Medical University, Saitama 350-1298, Japan.
Kazuyoshi HosomichiLaboratory of Computational Genomics, Tokyo University of Pharmacy and Life Sciences, Tokyo 192-0392, Japan.ORCID http://orcid.org/0000-0003-2712-1825
Atsushi WatanabeDivision of Clinical Genetics, Kanazawa University Hospital, Ishikawa 920-8640, Japan.ORCID http://orcid.org/0000-0001-9143-3079
Yuko NodaDepartment of Health Promotion and Medicine of the Future, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan.
Yoshiyu TakedaDepartment of Health Promotion and Medicine of the Future, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan.
Takashi YonedaDepartment of Health Promotion and Medicine of the Future, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan.ORCID http://orcid.org/0000-0002-0921-158X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pheochromocytoma is a rare form of adrenal hypertension. This study aimed to investigate the clinical characteristics and associated genetic mutations in patients with pheochromocytoma and primary aldosteronism. We retrospectively analyzed data from 23 patients with pheochromocytoma diagnosed and treated between 2011 and 2022. Three cases were complicated by primary aldosteronism. Compared to 15 other patients without primary aldosteronism complications, these three patients had a greater suppression of plasma renin activity (0.2 vs. 2.3 ng/mL/h, p < 0.01) and a higher aldosterone-to-renin ratio (p < 0.01). No significant differences were found in blood pressure, serum potassium levels, or plasma aldosterone concentrations between the two groups. In genetic analysis, among the three patients with pheochromocytoma and primary aldosteronism, two had a KCNJ5 (G151R) mutation in the pheochromocytoma tumor tissues. However, no CYP11B2- or CYP11B1-positive cells were detected via immunostaining in the pheochromocytoma tissues of these three patients. To our knowledge, this is the first study to reveal the presence of the KCNJ5 mutation, commonly considered specific to primary aldosteronism, in pheochromocytoma cases clinically complicated by primary aldosteronism. The findings suggest that patients with pheochromocytoma and suppressed plasma renin activity should be assessed for primary aldosteronism.

Indexed as

Adrenal Gland NeoplasmsG Protein-Coupled Inwardly-Rectifying Potassium ChannelsHyperaldosteronismPheochromocytomaAdolescentAdultAgedAged, 80 and overAldosteroneFemaleHumansJapanMaleMiddle AgedReninRetrospective StudiesAldosteroneG Protein-Coupled Inwardly-Rectifying Potassium ChannelsKCNJ5 protein, humanReninKCNJ5Next-generation sequencingPheochromocytomaPrimary aldosteronism

Identifiers

PMID39603607
PMCPMC11850107

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.